RxDoctor Payments Data

William Watterson, MD

Internal Medicine · Midlothian, VANPI 1578588976

Payments from drug & device makers

$10,740in general payments, 2019–2025

Across 669 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$890
  • Pfizer$634
  • Amgen$623
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$546
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$10,722100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,740 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$76,029
Medicare patients
144
Services billed
1,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol13$18,851
Repatha SureclickEvolocumab13$16,117
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,272
OzempicSemaglutide14$14,416
BelsomraSuvorexant19$12,298
Tresiba Flextouch U-200Insulin Degludec11$8,784
EliquisApixaban11$7,846
Buprenorphine14$3,320
Gabapentin78$1,557
Rosuvastatin Calcium200$1,519
SynthroidLevothyroxine Sodium15$1,289
Ezetimibe68$1,243
Bupropion XlBupropion Hcl48$1,025
Mirtazapine40$1,019
Bumetanide47$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,280$18,85113 claims
GSKTrelegy Ellipta$139$15,27221 claims
Novo NordiskOzempic$530$14,41614 claims
MerckBelsomra$131$12,29819 claims
PfizerEliquis$634$7,84611 claims
AbbVieSynthroid$1,962$1,28915 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$59759 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →